<DOC>
	<DOCNO>NCT03008512</DOCNO>
	<brief_summary>This study evaluate activity safety profile weekly Genexol-PM patient advance hepatocellular carcinoma sorafenib treatment fail . Patients receive Genexol-PM day 1 , 8 , 15 every 4 week .</brief_summary>
	<brief_title>A Phase II Study Weekly Genexol-PM Patients With Hepatocelluar Carcinoma After Failure Sorafenib</brief_title>
	<detailed_description>Hepatocelluar carcinoma ( HCC ) highly vascular neoplasm characterize arterial enhancement CT MRI . Angiogenesis provide target novel prognostic therapeutic approach HCC . Sorafenib standard 1st-line therapy show significantly improve overall survival advance HCC . However , sorafenib benefit mostly transient modest . In addition , sorafenib associate major toxicity , 30 % patient stop intolerance . Effective therapy need patient experience progression receive sorafenib sorafenib intolerance . Paclitaxel antiagiogenic activity weekly administration paclitaxel consider enhanced efficacy 3-weekly administration due great drug exposure direct antiangiogenic effect . A previous phase I study show weekly paclitaxel activity hepatocellular carcinoma investigation phase II trial warrant . Genexol-PM , cremophor-free , polymeric micelle-formulated paclitaxel , believe superior conventional paclitaxel term obviation premedication delivery high paclitaxel dos without additional toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>1 . A diagnosis hepatocellular carcinoma ( HCC ) base either 1. histopathologic cytologic finding 2. diagnosis cirrhosis HCC classical imaging characteristic ( least 3phase liver protocol CT MRI lesion demonstrate arterial enhancement wash venous phase ) 2 . Previous sorafenib treatment least 14 day discontinuation sorafenib treatment prior inclusion 3 . Radiologic confirmation disease progression discontinuation sorafenib treatment discontinuation sorafenib due intolerance despite appropriate supportive care 4 . Barcelona Clinic Liver Cancer ( BCLC ) stage C BCLC stage B disease amenable locoregional therapy refractory locoregional therapy 5 . ≥ 1 measurable lesion accord RECIST Version 1.1 6 . ≥ 20 year age 7 . ECOG performance status ≤ 2 8 . ChildPugh score ≤ 7 9 . Informed consent prior study 10 . Adequate organ function 1 . Hepatic : bilirubin ≤ 1.5 time upper limit institutional normal value ( ULN ) , AST ALT ≤ 5 x ULN 2 . Renal : estimate creatinine clearance ≥ 60 mL/min 3 . Hematologic : hemoglobin ≥ 9 g/dL , absolute neutrophil count ( ANC ) ≥ 1,500/μL , platelet ≥ 75,000/μL ( In case thrombocytopenia associate hypersplenism chronic liver disease , platelets ≥ 50,000/μL allow participation physician 's discretion . ) 4 . Coagulation : prothrombin time ( INR ) ≤ 1.5 , partial thrombin time ( PTT ) ≤ 5 second ULN 1 . Previous systemic chemotherapy advance disease ( except previous biologic agent include VEGF inhibitor , TGFbeta inhibitor , PD1/PDL1 blocker ) 2 . A history f current hepatic encephalopathy clinically meaningful ascites 3 . Grade 2 peripheral neuropathy 4 . Prior liver transplant 5 . History cancer within 2 year ( Patients carcinoma situ origin patient prior malignancy remission whose likelihood recurrence low , may eligible . ) 6 . A history treatment taxanes ( paclitaxel docetaxel ) 7 . Females pregnant lactate 8 . A know allergy hypersensitivity reaction treatment component 9 . Serious preexist medical condition adequately control appropriate therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Genexol-PM</keyword>
	<keyword>Neoplasms Site</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Neoplasms</keyword>
</DOC>